{
    "Patient": {
        "Name": "Christina Ingram",
        "DOB": "1960-09-01",
        "Sex": "Male",
        "Caseno": "1947",
        "Diagnosis": "Squamous cell carcinoma",
        "Physician": "Dr. Melanie Ochoa"
    },
    "specimen information": {
        "primary_tumor_site": "Lung",
        "specimen_site": "Bronchus",
        "specimen_ID": "7351",
        "CollectedDate": "2023-05-19",
        "ReceivedDate": "2023-05-20",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "15 m/Mb High",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 3+, 71%"
        },
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 1+, 88%"
        },
        {
            "BioMarker": "AR",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 3+, 2%"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "15 mutations/Mb High"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High - 22% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "SMO",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.N713_A714insKGKGGG",
            "Exon": 15,
            "DNA Alteration": "c.1924A>C",
            "Allele Frequency %": "30.25"
        },
        {
            "Gene": "APC",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.I1600M",
            "Exon": 6,
            "DNA Alteration": "c.4800C>G",
            "Allele Frequency %": "25.67"
        },
        {
            "Gene": "RNF43",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.N452D",
            "Exon": 7,
            "DNA Alteration": "c.1354A>G",
            "Allele Frequency %": "8.5"
        },
        {
            "Gene": "BRAF",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.*143Qext*31",
            "Exon": 10,
            "DNA Alteration": "c.427T>C",
            "Allele Frequency %": "20.11"
        },
        {
            "Gene": "SRSF2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.R132C",
            "Exon": 13,
            "DNA Alteration": "c.394_395delinsGT",
            "Allele Frequency %": "6.12"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "TLR8",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.R465H",
            "Exon": 6,
            "DNA Alteration": "c.1394G>A",
            "Allele Frequency %": "8.68"
        },
        {
            "Gene": "ALK",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.A34V",
            "Exon": 17,
            "DNA Alteration": "G",
            "Allele Frequency %": "20.1"
        },
        {
            "Gene": "H3.3",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.A374E",
            "Exon": 2,
            "DNA Alteration": "A",
            "Allele Frequency %": "3.21"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "ER",
            "Result": "Positive| 2+, 11%"
        },
        {
            "Biomarker": "PTEN",
            "Result": "Positive| 1+, 48%"
        },
        {
            "Biomarker": "MSH6",
            "Result": "Positive| 2+, 96%"
        },
        {
            "Biomarker": "PMS2",
            "Result": "Positive| 1+, 48%"
        },
        {
            "Biomarker": "ERBB2",
            "Result": "Positive| 2+, 61%"
        },
        {
            "Biomarker": "PD-L1(SP142)",
            "Result": "Negative| 3+, 46%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "FLT3",
        "ARHGAP45",
        "NT5C2",
        "PAX5",
        "XPC"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}